Literature DB >> 3434717

Treatment of the West syndrome with high-dose pyridoxal phosphate.

Y Ohtsuka1, M Matsuda, T Ogino, K Kobayashi, S Ohtahara.   

Abstract

Fifteen (12.7%) among 118 cases of the West syndrome were effectively treated by high-dose pyridoxal phosphate (PAL-P). 1) Clinical seizures were completely suppressed in 12 cases with PAL-P alone, and in 3 cases by an addition of PAL-P to the previously poorly-effective regimen. At the follow-up, 12 cases have continued to be free from seizures, while two cases relapsed into the Lennox-Gastaut syndrome, and one died. 2) Electroencephalographically hypsarhythmia disappeared by PAL-P in all 15 effective cases. 3) Effective daily dose of PAL-P was 30 to 400 mg. 4) Notably, PAL-P was effective even in the cases with obvious organic brain pathology, such as tuberous sclerosis, porencephaly, holoprosencephaly, postmeningitis, besides 5 idiopathic cases. 5) Efficacy of PAL-P was significantly higher in idiopathic cases than symptomatic cases; 35.7% vs 9.6%. 6) Response to PAL-P was not predictable by any laboratory data nor clinical features. 7) Prognosis of PAL-P responsive cases was favorable; as many as 6 cases developed normally among 14 cases followed-up. Treatment with a high-dose PAL-P should be tried in all cases of the West syndrome at first.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3434717     DOI: 10.1016/s0387-7604(87)80116-x

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  10 in total

Review 1.  A risk-benefit assessment of treatments for infantile spasms.

Authors:  R Nabbout
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

2.  Clinical characteristics of two cohorts of infantile spasms: response to pyridoxine or topiramate monotherapy.

Authors:  Jiao Xue; Ping Qian; Hui Li; Ye Wu; Hui Xiong; Yue-Hua Zhang; Zhi-Xian Yang
Journal:  World J Pediatr       Date:  2018-04-26       Impact factor: 2.764

3.  Evidence-based guideline update: medical treatment of infantile spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.

Authors:  C Y Go; M T Mackay; S K Weiss; D Stephens; T Adams-Webber; S Ashwal; O C Snead
Journal:  Neurology       Date:  2012-06-12       Impact factor: 9.910

4.  Infantile Spasms.

Authors:  Mary L. Zupanc
Journal:  Curr Treat Options Neurol       Date:  2001-05       Impact factor: 3.598

5.  The Clinical Features and Long-Term Follow-Up of Vitamin B6-Responsive Infantile Spasms in a Chinese Cohort.

Authors:  Xianru Jiao; Pan Gong; Yue Niu; Zhao Xu; Ye Wu; Yuehua Zhang; Zhixian Yang
Journal:  Front Neurol       Date:  2022-05-12       Impact factor: 4.086

Review 6.  Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society.

Authors:  M T Mackay; S K Weiss; T Adams-Webber; S Ashwal; D Stephens; K Ballaban-Gill; T Z Baram; M Duchowny; D Hirtz; J M Pellock; W D Shields; S Shinnar; E Wyllie; O C Snead
Journal:  Neurology       Date:  2004-05-25       Impact factor: 9.910

Review 7.  Recent advances in amino acid and organic acid metabolism.

Authors:  J V Leonard
Journal:  J Inherit Metab Dis       Date:  2007-01-19       Impact factor: 4.750

Review 8.  Metabolic etiologies in West syndrome.

Authors:  Seda Salar; Solomon L Moshé; Aristea S Galanopoulou
Journal:  Epilepsia Open       Date:  2018-03-14

9.  Current trends in the treatment of infantile spasms.

Authors:  Chang-Yong Tsao
Journal:  Neuropsychiatr Dis Treat       Date:  2009-05-20       Impact factor: 2.570

10.  An effective initial polytherapy for children with West syndrome.

Authors:  Feiyong Jia; Huiyi Jiang; Lin Du; Ning Li; Ji Sun; Chunbo Niu
Journal:  Neural Regen Res       Date:  2013-06-15       Impact factor: 5.135

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.